SCHEMBL24378005

SCHEMBL24378005

Cn1cc(CNC(=O)C2CN(C(=O)CCl)c3ccccc3O2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HPGD P15428 2/20 0.43
HTT P42858 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
CHRM1 P11229 3/20 0.42
SIRT1 Q96EB6 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29516400 0.85 MAPK1 (0.54) MAPK1L3MBTL1HPGDHTTCYP1A2
SCHEMBL24377989 0.85 MAPK1 (0.54) MAPK1L3MBTL1HPGDHTTCYP1A2
SCHEMBL29516475 0.79 KMT2A (0.49) HPGDRAB9AKMT2AMEN1SIRT1
SCHEMBL24378149 0.79 KMT2A (0.49) HPGDRAB9AKMT2AMEN1SIRT1
SCHEMBL24378142 0.77 KMT2A (0.41) CYP1A2CYP3A4CYP2C9CYP2C19RAB9A
SCHEMBL24377952 0.77 F2 (0.46) HPGDHTTRAB9ATSHRKMT2A
SCHEMBL29516358 0.76 HPGD (0.60) MAPK1L3MBTL1HPGDHTTCYP1A2
SCHEMBL24377990 0.76 HPGD (0.60) MAPK1L3MBTL1HPGDHTTCYP1A2
SCHEMBL26938745 0.75 SIRT1 (0.51) HPGDRAB9AKMT2AMEN1SIRT1
SCHEMBL26938724 0.75 SIRT1 (0.51) HPGDRAB9AKMT2AMEN1SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
WO-2022087433-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER CKMT1A; CKMT1B, PHKG1, PCK1 MAPK1 1540/4885L3MBTL1 1387/4885HPGD 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.